Company / Current Liabilities
Theravance Biopharma, Inc. Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$38.3M
FY2025
5-year range
$24.8M / $58.6M
FY2021-FY2025
Trend
+19.4%
vs FY2024
Sector context
#162 of 213
Health Care
What the data says
Theravance Biopharma, Inc.'s current liabilities of $38M is lower than 76% of companies in the Health Care sector (FY2025). Increased from $25M to $38M over the past 2 years.
Based on SEC 10-K filings.
$38M in FY2025 with a 5-year CAGR of -20.9%.
Increased from $25M to $38M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +10.1%
- 5-Year CAGR
- -20.9%
- 10-Year CAGR
- -
Sector benchmark
Top 24% in Health CareTop 24% of 213This company $38.3M Sector average $1.6B
▼
-97.6% below sector average
Key checks
Key Insights
- 5-year CAGR of -20.9%, indicating a declining trend.
- In FY2025, current liabilities increased 19.4% year-over-year.
- Ranks #162 out of 213 companies in the Health Care sector.
- Peak current liabilities was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $38.3M | +19.4% |
| FY2024 | $32.1M | +29.5% |
| FY2023 | $24.8M | -13.7% |
| FY2022 | $28.7M | -51.0% |
| FY2021 | $58.6M | -52.6% |
| FY2020 | $123.6M | +10.6% |
| FY2019 | $111.7M | +13.3% |
| FY2018 | $98.6M | +57.6% |
| FY2017 | $62.6M | +27.0% |
| FY2016 | $49.3M | -0.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026